BioNTech SE ADR Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
6.5%projected annual EPS growth
Analyst Coverage
20analysts covering
FY EPS (est.)
-$5.83next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| 2026 Q3 Earnings Call and Corporate Update | 3 Nov 2026 |
Monitoring Framework
Key Performance Indicators
COVID-19 & Combined Vaccine Revenue / Guidance Execution Quarterly / Annual IR Filings€2.0B - €2.3B (2026 Guidance Midpoint: €2.15B)Target: €2.75B (Analyst Consensus Baseline)
Total Cash, Cash Equivalents, and Security Investments Quarterly17.2BTarget: Maintain strong capital reserves to fund oncology pipeline transition
Adjusted Research and Development Expenses AnnuallyTarget: €2.2 billion to €2.5 billion for the 2026 financial year
Watch Items
- Pumitamig (PD-L1 x VEGF-A bispecific antibody) clinical trial readoutsTrigger: Presentation of overall survival and efficacy data from Phase 2/3 trials (e.g., ROSETTA Lung-02)Action: Evaluate competitive positioning in first-line non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC)
- Gotistobart (anti-CTLA-4 antibody) clinical trial readoutsTrigger: Phase 3 data in second-line squamous NSCLC and Phase 2 data in platinum-resistant ovarian cancerAction: Assess potential as a chemotherapy-free treatment option and regulatory filing timelines
- Multi-billion dollar patent litigation regarding lipid nanoparticle (LNP) delivery technologyTrigger: Court rulings or potential settlement announcements with competitors (e.g., Arbutus, Genevant)Action: Quantify financial impact on cash reserves and evaluate potential royalty obligations
Research as of 2 Sep 2026